Previous 10 | Next 10 |
Matinas BioPharma Holdings, Inc. (MTNB) Q3 2021 Earnings Conference Call November 08, 2021, 08:30 AM ET Company Participants Peter Vozzo - Investor Relations Jerome Jabbour - Chief Executive Officer Keith Kucinski - Chief Financial Officer Terry Ferguson - Chief Medical Officer Terry Matkovit...
Matinas Biopharma (NYSE:MTNB): Q3 GAAP EPS of -$0.03 misses by $0.01. Cash, cash equivalents and marketable securities at September 30, 2021, were approximately $53.8M, compared to $58.7M at December 31, 2020 Shares +0.93% PM. Press Release For further details see: Matinas Biopharma EPS...
– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study – – Dosing...
Matinas Biopharma (NYSE:MTNB) is scheduled to announce Q3 earnings results on Monday, November 8th, before market open. The consensus EPS Estimate is -$0.03 (flat Y/Y) and the consensus Revenue Estimate is $1.53M (+1600.0% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revisio...
AVDL, AXSM, BKI, COTY, CTRE, DS,EDIT, EHTH, IMOS, KOS, LINC, LTBR, MTNB, NERV, OCN, PSEC, RDUS, RETA, TGLS, THS, TSEM, TTD, TYME, USFD, VAC, VTRS, WOW For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
BEDMINSTER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery...
BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform...
BEDMINSTER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform...
Marine Petroleum Trust (NASDAQ:MARPS) +52%. U.S. Energy USEG +23% new assets to nearly quadruple production Annovis Bio (NYSE:ANVS) +16% announces positive phase 2 efficacy data for the treatment of parkinson's disease Team TISI +14% wins upstream mechanical insp...
Puhui Wealth Investment (NASDAQ:PHCF) +55%. Red Cat Holdings RCAT +50% after subsidiary receives five-year contract with NASA Paltalk (NASDAQ:PALT) +36%. Vinco Ventures (NASDAQ:BBIG) +16%. VIZIO Holding (NYSE:VZIO) +10%. U.S. Energy (NASDAQ:USEG) +8%. Syndax Pharmaceuticals (NASDAQ:...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
Matinas Biopharma Holdings Inc. Website:
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its ora...
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data ...